• Di Zhao, Hui Liu, Shifang Chen, and Pingshuan Dong.
• Bratisl Med J. 2023 Jan 1; 124 (5): 380386380-386.

ObjectiveWe performed this meta-analysis determining the antihypertensive effect of telmisartan versus perindopril in patients with essential hypertension.BackgroundThe comparison of antihypertensive effects between telmisartan and perindopril were controversial.MethodsPubmed, Web of Science, and Cochrane Central were searched for all published studies.ResultsThe antihypertensive effects were assessed in 753 patients included in 7 trials with a mean follow-up of 20 ± 16 weeks. There was no significant difference between telmisartan and perindopril in reduction of systolic blood pressure (SBP, weighted mean differences (WMD) 0.02 (95% confidence interval (CI), ‒2.78, 2.81) mm Hg, p > 0.05). The reduction of diastolic BP (DBP) treated with telmisartan was greater than perindopril in these patients (WMD ‒2.05 (95% CI, ‒2.60, ‒1.49) mm Hg, p < 0.001). Considering the effects of different doses on BP reduction, a sub-analysis was performed. The reduction of DBP treated with 40 mg/day telmisartan was greater than 4‒5 mg/day perindopril (WMD ‒2.18 (95% CI, ‒2.83, ‒1.53) mm Hg, p 0.05).ConclusionThe reduction of DBP is greater treated with telmisartan than perindopril in patients with essential hypertension (Tab. 2, Fig. 4, Ref. 34). Text in PDF www.elis.sk Keywords: essential hypertension, blood pressure, telmisartan, perindopril, meta-analysis.

16 keywords...

hide…